10 Stocks Wall Street Is Calling Bullish Amid Market Turmoil
The S&P 500 is down 8.6% in a month while the Nasdaq has lost nearly 13%.
Nektar Therapeutics (NKTR)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Samlyn Capital Robert Pohly | 9,667,048 | $8,990,355 | +6% | 0.13% |
| 2. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 7,810,000 | $7,263,300 | +91% | 0.31% |
| 3. | Woodline Partners Michael Rockefeller And Karl Kroeker | 4,974,512 | $4,626,296 | +188% | 0.03% |
| 4. | Millennium Management Israel Englander | 4,524,946 | $4,208,200 | -11% | 0% |
| 5. | Renaissance Technologies Jim Simons | 3,910,786 | $3,637,031 | +18% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $17.28 | 15,000 | Officer | 107,668 | 2019-09-05 | Filing | |
| $59.80 | 1,400 | Director | 177,000 | 2018-06-06 | Filing | |
| $59.07 | 2,000 | Director | 175,600 | 2018-06-06 | Filing | |
| $55.22 | 1,600 | Director | 173,600 | 2018-06-05 | Filing | |
| $17.95 | 35,000 | Director | 133,000 | 2017-08-10 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.01 | 10,300 | 316,604 | 2025-02-19 | Filing | ||
| $1.01 | 11,040 | 324,292 | 2025-02-19 | Filing | ||
| $1.01 | 23,774 | 1,086,901 | 2025-02-19 | Filing | ||
| $0.89 | 16,560 | 335,332 | 2024-12-24 | Filing | ||
| $0.90 | 33,402 | 351,892 | 2024-12-23 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 221,761 | $150,788 | 0% | |
| 2. | 34,465 | $23,436 | 0% | |
| 3. | 29,930 | $20,352 | 0% | |
| 4. | 15,820 | $10,758 | 0% | |
| 5. | 13,000 | $8,840 | 0% |
News See All
Nektar Therapeutics (NASDAQ:NKTR) Q4 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Nektar Therapeutics Fourth Quarter 2024 financial results conference call. At this time, all participants are in a listen-only mode.
12 Best Penny Stocks to Invest in According to the Media
On December 24, Global Advisors’ managing partner, Tom Lee, shared his thoughts on the potential of small and mid-cap stocks in 2025.
Nektar Therapeutics (NASDAQ:NKTR) Q3 2024 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Nektar Therapeutics' Third Quarter 2024 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Nektar Therapeutics (NASDAQ:NKTR) Q1 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Nektar Therapeutics First Quarter 2024 Financial Results Conference Call. [Operator Instructions].
Nektar Therapeutics (NASDAQ:NKTR) Q4 2023 Earnings Call Transcript
Nektar Therapeutics misses on earnings expectations. Reported EPS is $-0.22 EPS, expectations were $-0.2.
Nektar Therapeutics (NASDAQ:NKTR) Q3 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Nektar Therapeutics Third Quarter 2023 Financial Results Conference Call.
12 Best Penny Stocks to Buy Under $1
Investors are optimistic as we move into the third quarter earnings season.
Nektar Therapeutics (NASDAQ:NKTR) Q2 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Nektar Therapeutics Second Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Nektar Therapeutics (NASDAQ:NKTR) Q1 2023 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Nektar Therapeutics First Quarter 2023 Financial Results Conference Call.
Billionaire Hedge Funds
